Exhibit 99.1

                                [HALOZYME THERAPEUTICS LOGO]

HALOZYME CONTACT                            INVESTOR RELATIONS CONTACTS
David A. Ramsay                             Ina McGuinness / Bruce Voss
Chief Financial Officer                     Lippert/Heilshorn & Associates
(858) 794-8889                              (310) 691-7100
dramsay@halozyme.com                        imcguinness@lhai.com

                                            MEDIA CONTACTS
                                            Kathy Sweeney / Joleen Schultz
                                            Mentus
                                            (858) 455-5500, x230/x215
                                            kwitz@mentus.com
                                            jschultz@mentus.com

                   HALOZYME THERAPEUTICS NAMES STEVE THORNTON
                              TO BOARD OF DIRECTORS

SAN DIEGO, JULY 6, 2005 - Halozyme Therapeutics, Inc. (AMEX: HTI), a
biopharmaceutical company focused on the development and commercialization of
recombinant human enzymes, today announced that Steve Thornton has been named to
its Board of Directors. Mr. Thornton is President of SkyePharma, Inc., which
develops and manufactures injectable, sustained-release therapeutic products.

"We are thrilled to welcome Steve to our Board," said Jonathan Lim, MD,
Halozyme's Chairman and CEO. "Steve brings over 27 years of broad experience
working with branded and generic drugs, medical devices, and drug delivery
technologies within both large and small pharmaceutical companies. Steve's
career has taken him through a variety of sales and marketing positions
culminating in managing fully integrated businesses in the US, Europe, and
Australia. He will bring invaluable strategic and operational experience to
Halozyme, especially as we commercialize our first products."

As Executive Vice President of Business Development at Elan, and in his current
role, Mr. Thornton has been involved in a significant number of business
development activities and partnerships across the industry, with both major
pharmaceutical and emerging biotechnology companies. As part of this role, he
represented Elan on a number of joint venture boards with biotechnology
partners, giving him insight into the workings of relatively early company
organizations. He is highly experienced in the areas of in- and out-licensing of
products and has been involved in a variety of start-up operations, joint
ventures and acquisitions. Mr. Thornton has also held senior executive positions
at Eli Lilly and Bayer.



ABOUT HALOZYME THERAPEUTICS, INC.

Halozyme is a development stage biopharmaceutical company dedicated to
developing and commercializing recombinant human enzymes for the infertility,
ophthalmology, and oncology communities. The company's portfolio of products
under development is based on intellectual property covering the family of human
enzymes known as hyaluronidases. Halozyme's recombinant human enzymes may
replace current animal slaughterhouse-derived enzymes that carry potential risks
of animal pathogen transmission and immunogenicity. The versatility of the first
enzyme, rHuPH20, enables Halozyme to develop the product as a medical device,
drug enhancement agent, and therapeutic biologic.

SAFE HARBOR STATEMENT

In addition to historical information, the statements set forth above include
forward-looking statements (including, without limitation, statements concerning
the progress towards commercializing its first products) that involve risk and
uncertainties that could cause actual results to differ materially from those in
the forward-looking statements. The forward-looking statements are also
identified through use of the words "believe," "enable," "may," "will," "could,"
"intends," "estimate," "anticipate," "plan," "predict," "probable," "potential,"
"possible," "should," "continue," and other words of similar meaning. Actual
results could differ materially from the expectations contained in
forward-looking statements as a result of several factors, including regulatory
approval requirements and competitive conditions. These and other factors that
may result in differences are discussed in greater detail in the company's
reports on Forms 10-KSB, 10-QSB and other filings with the Securities and
Exchange Commission.

                                       ###